Jardiance is a New Type 2 Diabetes Medication
August 1, 2014 – Jardiance (empagliflozin) was approved by The Food and Drug Administration (FDA) to help fight type 2 diabetes. Jardiance is manufactured by Boehringer Ingelheim Pharmaceuticals and it is classified as a sodium glucose co-transporter 2 (SGLT2) inhibitor which works by stopping blood sugar or glucose from getting reabsorbed into the Kydneys.
Jardiance provides the option of being used along or in addition to existing treatment to control blood sugar levels for patients with type 2 diabetes for long term management of the disease. It is recommended that Jardiance also be used in conjunction with appropriate lifestyle changes that include healthy diet and exercise.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.